As in previous years, our experts were attending the US Pharma Market Research Conference in New Jersey on February 8-9, 2023.
It was a pleasure to discuss with you and to share the latest news!
We are looking forward to EU PMRC in Roma next March 30-31. 👋
🎙️ INTELLUS 🎙️
Meet our experts at Intellus Worldwide on March 1-3 in Philadelphia.
Don't miss our talk if you are there: Thursday, March 2 at 11:40 – 12:30 ET US 👇 "Dr. Jekyll and Mr. Hyde's market research outputs: can a lobectomy help?"
Discover alternative ways to traditional visualization for large datasets, allowing researchers and marketers to unlock previously hidden insights.
To learn more on how this can be applied to your projects, contact us to arrange a meeting during Intellus or for a complimentary consultation.
🔎 The Social Media Impact of the 64th ASH meeting 🔎
What subjects were amplified by HCPs and by Pharma companies through social media during ASH22?
Last December, took place the 64th ASH Annual Meeting.
The following blog post provide an overview of the volume of conversations during the meeting, the top hashtags, or the share of voice of medical conditions most discussed by HCPs and by pharma companies.
New syndicated studies are launched by APLUSA every month!
Interested in more of our other syndicated studies? Click here!
Syndicated Tracker on CMV
in Transplant Patients
The survey covers 9 countries, the USA, EU5, Japan, Brazil, and China, with 85 specialists per country -125 in the USA. The survey is now in field for results this Spring.
CMVsyndiTrack™ will provide you with a detailed assessment of CMV market in transplanted patients: current management, and opportunities for future treatments.
We have back-data from the USA, UK, FR, DE, IT, ES, and a new wave is launching in 2023 in the UK, DE, FR, IT, ES, AU, CA, BE, CH, NL, PL, and IL.
Hematologists/oncologists provide data on their medical practice as well as current and historical information from 5 to 7 randomly selected R/R DLBCL patient charts.
🗣️ Did you watch our latest episode of DoctoLIVE? 🗣️
Our APLUSA expert interviewed an hemato-oncologist who has participated in our multiple myeloma studies for more than 10 years. 💡This new DoctoLIVE session provides you with exclusive insights from our MMsyndiTrack™ study and how they resonate with actual clinical practice. They discuss the consequences of recent clinical developments related to Multiple Myeloma including CAR-T and bispecific antibodies.
APLUSA is once again proud to sponsor the 2023 MR Excellence Awards organized by EphMRA. The "Innovative Approach Award" will be judged according to these criteria: •Clarity of presentation and message conveyed •Level of innovation demonstrated
•Level of added value the innovative approach provided compared to more traditional approaches
Don't miss your chance to win one of the 3 awards up for grabs this year!
Our experts provide you with inspiring and educational content on how to conduct market research, best practices, tips, and examples of research results that open up leads for better future research! Browse through this section and discover various educational content.
These last few months have been full of new arrivals! We were very excited to warmly welcome about twenty new collaborators in our Lyon, Paris, London and Newark offices.
.png?upscale=true&width=1192&upscale=true&name=AplusA%20Events%20participation%20(6).png)
.gif?upscale=true&width=516&upscale=true&name=Syndicated%20Promotion%20(3).gif)
.png?upscale=true&width=1112&upscale=true&name=AplusA%20Events%20participation%20(2).png)
.gif?upscale=true&width=1192&upscale=true&name=New%20APLUSIANS%20(1).gif)
